[GLP-1 receptor agonists : impact on diabetic kidney disease].
Madeleine WéraNicolas PaquotPublished in: Revue medicale suisse (2024)
In addition to optimal glycemic control and management of other factors aggravating the pathology (hypertension, dyslipidemia, -obesity), the cornerstone of treatment of diabetic kidney disease (DKD) includes blockers of the renin-angiotensin system, sodium-glucose cotransporter 2 inhibitors or nonsteroidal antagonists of the mineralocorticoid receptor (finerenone). Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are recommended in the treatment of high-risk patients with type 2 diabetes (T2DM) to reduce cardiovascular (CV) risk. Data from CV studies indicate a nephroprotective effect of certain GLP-1 RAs in T2DM patients with DKD. The FLOW study published in May 2024, analyzing the impact of semaglutide vs placebo on renal events as primary outcome, confirms this renal protection of GLP-1 RAs.
Keyphrases
- glycemic control
- type diabetes
- weight loss
- insulin resistance
- metabolic syndrome
- wild type
- systematic review
- clinical trial
- blood glucose
- combination therapy
- electronic health record
- wound healing
- big data
- skeletal muscle
- angiotensin converting enzyme
- artificial intelligence
- high fat diet induced
- open label
- smoking cessation